Oral Contraceptive Use, Colorectal Cancer: Possible Relationships
the Cancer Therapy Advisor take:
A potential association was recognized between oral contraceptive (OC) use by younger women for long durations and possible protection for colorectal cancer, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
The researchers analyzed and categorized OC use every 2 years from 1976 to 2010 using data of 88,691 participants in the Nurses’ Health Study I (NHSI) and of 93,080 participants in the Nurses’ Health Study II (NHSII).
The categories that were established included ever use, duration of use, and time since last use. All incident colorectal cancer cases from NHSI and NHSII through 2010 were included in the analysis (age at diagnosis = 36–88, N = 1,764 and age at diagnosis = 33–64, N = 206, respectively).
Results showed ever OC use was not related to colorectal cancer incidence in NHSI nor in NHSII [1.01 (0.91, 1.12) and 1.03 (0.69, 1.53), respectively.]
The longer duration (5+ years) OC use cohort in NHSII was inversely associated with the risk of colon cancers (Ptrend = 0.02) compared to never-users—although endpoints were limited.
Little evidence was found to support an association between OC use and protection against colorectal cancer; however, the potential association between longer duration OC use by younger women warrants further study.
A potential association was recognized between oral contraceptive use by younger women and protection for colorectal cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma